European CHMP adopts positive opinion for Gilead’s Epclusa to treat all genotypes of chronic hepatitis C
The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection. The CHMP positive opinion was adopted following
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.